NCT05457699: ANCHORProstate

Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

Recruiting now Phase 2 Last updated 8 April 2026

What this trial tests

Phase 2 trial testing Metastasis directed radiotherapy (MDRT) in Prostate Cancer Metastatic in 80 participants. Currently enrolling.

Timeline

30 December 2022

Primary endpoint
30 July 2030

30 July 2030

Quick facts

Lead sponsor	Centre hospitalier de l'Université de Montréal (CHUM)
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	80
Start date	30 December 2022
Primary completion	30 July 2030
Estimated completion	30 July 2030
Sites	1 location across Canada

Drugs / interventions tested

• Metastasis directed radiotherapy (MDRT)
• no MDRT

Conditions studied

• Prostate Cancer Metastatic — all drugs for Prostate Cancer Metastatic →

Sponsor

Centre hospitalier de l'Université de Montréal (CHUM)

Who can join

Eligibility, male only, with Prostate Cancer Metastatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This will be a pragmatic, phase II, registry-based cohort-multiple randomized controlled trial (cmRCT) embedded within an ongoing prospective cancer radiotherapy registry. Eligible patients are those with hormone-sensitive metastatic prostate cancer who have responded to systemic therapy, defined by the absence of PSA progression, and who are eligible for MDRT. All eligible subjects will be enrolled into the registry and followed longitudinally for oncologic and toxicity outcomes.

From this registry, patients will be randomly selected (1:1) to be offered the experimental arm, which consists of MDRT delivered to metastatic sites identified on imaging in patients who have already initiated systemic therapy (Figure 1). Those not selected will continue to receive standard of care systemic therapy +/- standard of care radiotherapy if clinically indicated. Nor patients or physicians will be blinded.

Following the initial course of MDRT, prostate-specific antigen (PSA) will be measured, with a minimum assessment at 3 months. This PSA value will be used to determine whether the PSA level has decreased below 0.2 ng/mL. If the PSA remains ≥ 0.2 ng/mL, repeat PSMA-PET will be performed, and a second course of MDRT will be delivered to consolidate residual metastatic lesions.

In this phase II real-world randomized trial, we will determine if AnChoRing (Addition of MDRT for consolidation of response) sites of PSMA PET visible disease when responding to systemic therapy improves the proportion of patients achieving a PSA \< 0.2 ng/mL and extends failure-free survival compared to the standard of care.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Platform for the Evaluation of innovations in Radiation oncology through registry-based conduct of multi-centric pragmatic randomized trials: PERa implementation.
   Giguère P, Bahig H, Westra S, Roberge D, et al · · 2026 · PMID 42032732 · DOI 10.1186/s13063-026-09709-0